News
NGEN
1.630
+20.74%
0.280
NervGen Says FDA Grants NVG-291 Breakthrough Therapy Designation For Treatment Of Chronic Traumatic Cervical Motor-Incomplete SCI
Benzinga · 12h ago
Weekly Report: what happened at NGEN last week (1102-1106)?
Weekly Report · 3d ago
NervGen’s Spinal Cord Injury Trial Reaches Completion, but Results Remain Key
TipRanks · 11/05 16:30
Weekly Report: what happened at NGEN last week (1026-1030)?
Weekly Report · 11/02 09:05
Weekly Report: what happened at NGEN last week (1019-1023)?
Weekly Report · 10/26 09:05
Weekly Report: what happened at NGEN last week (1012-1016)?
Weekly Report · 10/19 09:05
NervGen Pharma doses first participant in RESTORE trial
TipRanks · 10/12 11:20
NervGen Doses First Participant In Phase 3 RESTORE Study Of NVG-291 For Chronic Cervical SCI; Enrollment Completion Expected In H2 2027, Topline Data In H1 2028
Benzinga · 10/12 11:17
Weekly Report: what happened at NGEN last week (1005-1009)?
Weekly Report · 10/12 09:05
Weekly Report: what happened at NGEN last week (0928-1002)?
Weekly Report · 10/05 09:05
NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything
Seeking Alpha · 10/01 21:26
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), United Therapeutics (UTHR) and NervGen Pharma (NGEN)
TipRanks · 10/01 18:00
Weekly Report: what happened at NGEN last week (0921-0925)?
Weekly Report · 09/28 09:05
NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results
TipRanks · 09/25 20:59
NervGen Pharma to restate previously filed financial statements
TipRanks · 09/25 20:40
*NervGen Pharma: Expects to File Restated Audited Financial Statements for Year Ended Dec. 31, 2025, Including Restated 2024 Comparative Figure and Adjustment to Jan. 1, 2024, Opening Balances >NGEN
Dow Jones · 09/25 20:35
NervGen Announces It Will Restate Its Audited Annual Financial Statements For The Year Ended December 31, 2025, And Its Unaudited Interim Financial Statements For The Quarter Ended June 30, 2026
Benzinga · 09/25 20:34
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Accumulated Deficit >NGEN
Dow Jones · 09/25 20:34
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Warrant Liabilities >NGEN
Dow Jones · 09/25 20:34
*NervGen Pharma: Restatement Expected to Reduce Previously Reported Stock-Based Compensation Expense >NGEN
Dow Jones · 09/25 20:33
More
Webull provides a variety of real-time NGEN stock news. You can receive the latest news about Nervgen Pharma Corp through multiple platforms. This information may help you make smarter investment decisions.
About NGEN
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.